

Fig. 1




Fig. 2




Fig. 3



Fig. 4




Fig. 5





Fig. 6

Fig. 7




Fig. 7a

Fig. 7b

Fig. 8




Fig. 9




Fig. 9a

Fig. 9b

Fig. 10




Fig. 11




Fig. 12A.




Fig. 12B.

	WB	WB
	Comp	Fas-Comp
IVIG	Negative	Positive
98J30AB12	Negative	Positive
99A18AB11	Negative	Positive
98K13AB12	Negative	Positive
2620M081A	Negative	Positive
99A13AB11	Negative	Positive
2453397F	Negative	Positive
2456898I	Negative	Positive
2470797G	Negative	Positive
2454198F	Negative	Positive
2470597G	Negative	Positive
Sandoglobulin	Negative	Positive
Anti-Fas Apo1	Negative	Positive
Vehicle	Negative	Negative

A.





Fig. 2B.

IVIG	FasL ELISA Inhibition		Categories
	% Max at 30 mg/ml		
98J30AB12		45	2
99A18AB11		49	2
98K13AB12		49	2
2620M081A		60	Best
99A13AB11		44	2
2453397F		26	Worst
2456898I		36	3
2470797G		39	3
2454198F		45	2
2470597G		48	2
Sandoglobulin		35	3
Vehicle	100% binding		
	1 hr Preincubation		

Fig. 2C.



A.





Fig. 14 B.

IVIG	FasL Killing Inhibition		Categories
	Start mg/ml	Peak mg/ml	
98J30AB12	0.5	4	2
99A18AB11	1	8	3
98K13AB12	1	8	3
2620M081A	2	8	4
99A13AB11	1	15	4
2453397F	1	4	2
2456898I	1	4	2
2470797G	1	4	2
2454198F	0.25	8	Best
2470597G	0.25	8	Best
Sandoglobulin	15	30	Worst
Vehicle	Negative	Negative	
	No Preincubation	No Preincubation	

Fig. 14C.



Mme. N. A. (1958) GVHD

IVIG





Fig 15A

Anti-Fas certified IVIG



Anti-fas certified IVIG

Fig. 15B